Loading...
PPGN logo

PolyPeptide Group AGSWX:PPGN Stock Report

Market Cap CHF 824.8m
Share Price
CHF 25.00
My Fair Value
CHF 35.6
29.8% undervalued intrinsic discount
1Y-13.0%
7D5.5%
Portfolio Value
View

PolyPeptide Group AG

SWX:PPGN Stock Report

Market Cap: CHF 824.8m

PolyPeptide Group (PPGN) Stock Overview

Operates as a contract development and manufacturing company in Europe, the United States, and India. More details

PPGN fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance0/6
Financial Health4/6
Dividends0/6

PPGN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

CHF 33.1
FV
24.5% undervalued intrinsic discount
11.03%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
about 1 year ago author updated this narrative
US$5.3
70.2% undervalued intrinsic discount
Revenue growth
N/A
Profit Margin
30%
Future PE
20x
Share price in 2030
US$0

PolyPeptide Group AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for PolyPeptide Group
Historical stock prices
Current Share PriceCHF 25.00
52 Week HighCHF 33.40
52 Week LowCHF 13.22
Beta1.11
1 Month Change-3.85%
3 Month Change23.15%
1 Year Change-13.04%
3 Year Change-14.85%
5 Year Changen/a
Change since IPO-68.03%

Recent News & Updates

PolyPeptide Group (VTX:PPGN) Is Carrying A Fair Bit Of Debt

Sep 25
PolyPeptide Group (VTX:PPGN) Is Carrying A Fair Bit Of Debt

Earnings Update: Here's Why Analysts Just Lifted Their PolyPeptide Group AG (VTX:PPGN) Price Target To CHF31.29

Aug 16
Earnings Update: Here's Why Analysts Just Lifted Their PolyPeptide Group AG (VTX:PPGN) Price Target To CHF31.29

PolyPeptide Group AG's (VTX:PPGN) Shares Leap 28% Yet They're Still Not Telling The Full Story

Aug 15
PolyPeptide Group AG's (VTX:PPGN) Shares Leap 28% Yet They're Still Not Telling The Full Story

Recent updates

PolyPeptide Group (VTX:PPGN) Is Carrying A Fair Bit Of Debt

Sep 25
PolyPeptide Group (VTX:PPGN) Is Carrying A Fair Bit Of Debt

Earnings Update: Here's Why Analysts Just Lifted Their PolyPeptide Group AG (VTX:PPGN) Price Target To CHF31.29

Aug 16
Earnings Update: Here's Why Analysts Just Lifted Their PolyPeptide Group AG (VTX:PPGN) Price Target To CHF31.29

PolyPeptide Group AG's (VTX:PPGN) Shares Leap 28% Yet They're Still Not Telling The Full Story

Aug 15
PolyPeptide Group AG's (VTX:PPGN) Shares Leap 28% Yet They're Still Not Telling The Full Story

Does PolyPeptide Group (VTX:PPGN) Have A Healthy Balance Sheet?

May 23
Does PolyPeptide Group (VTX:PPGN) Have A Healthy Balance Sheet?

PolyPeptide Group AG (VTX:PPGN) Might Not Be As Mispriced As It Looks After Plunging 28%

Apr 08
PolyPeptide Group AG (VTX:PPGN) Might Not Be As Mispriced As It Looks After Plunging 28%

Why PolyPeptide Group AG (VTX:PPGN) Could Be Worth Watching

Feb 04
Why PolyPeptide Group AG (VTX:PPGN) Could Be Worth Watching

Many Still Looking Away From PolyPeptide Group AG (VTX:PPGN)

Jan 09
Many Still Looking Away From PolyPeptide Group AG (VTX:PPGN)

PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 19% Below Its Share Price

Nov 11
PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 19% Below Its Share Price

PolyPeptide Group (VTX:PPGN) Is Making Moderate Use Of Debt

Oct 21
PolyPeptide Group (VTX:PPGN) Is Making Moderate Use Of Debt

Sentiment Still Eluding PolyPeptide Group AG (VTX:PPGN)

Sep 16
Sentiment Still Eluding PolyPeptide Group AG (VTX:PPGN)

Does PolyPeptide Group (VTX:PPGN) Have A Healthy Balance Sheet?

Jun 19
Does PolyPeptide Group (VTX:PPGN) Have A Healthy Balance Sheet?

Further Upside For PolyPeptide Group AG (VTX:PPGN) Shares Could Introduce Price Risks After 33% Bounce

Mar 14
Further Upside For PolyPeptide Group AG (VTX:PPGN) Shares Could Introduce Price Risks After 33% Bounce

PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 99% Above Its Share Price

Mar 13
PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 99% Above Its Share Price

PolyPeptide Group AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 18
PolyPeptide Group AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Investors Shouldn't Be Too Comfortable With PolyPeptide Group's (VTX:PPGN) Robust Earnings

Mar 23
Investors Shouldn't Be Too Comfortable With PolyPeptide Group's (VTX:PPGN) Robust Earnings

Shareholder Returns

PPGNCH Life SciencesCH Market
7D5.5%5.6%4.0%
1Y-13.0%-4.3%3.0%

Return vs Industry: PPGN underperformed the Swiss Life Sciences industry which returned -4.3% over the past year.

Return vs Market: PPGN underperformed the Swiss Market which returned 3% over the past year.

Price Volatility

Is PPGN's price volatile compared to industry and market?
PPGN volatility
PPGN Average Weekly Movement7.7%
Life Sciences Industry Average Movement4.8%
Market Average Movement3.7%
10% most volatile stocks in CH Market7.5%
10% least volatile stocks in CH Market1.7%

Stable Share Price: PPGN's share price has been volatile over the past 3 months compared to the Swiss market.

Volatility Over Time: PPGN's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Swiss stocks.

About the Company

FoundedEmployeesCEOWebsite
19521,400Juan Gonzalezwww.polypeptide.com

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1.

PolyPeptide Group AG Fundamentals Summary

How do PolyPeptide Group's earnings and revenue compare to its market cap?
PPGN fundamental statistics
Market capCHF 824.79m
Earnings (TTM)-CHF 32.42m
Revenue (TTM)CHF 344.43m
2.4x
P/S Ratio
-25.4x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PPGN income statement (TTM)
Revenue€368.85m
Cost of Revenue€327.33m
Gross Profit€41.52m
Other Expenses€76.24m
Earnings-€34.72m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

Mar 12, 2026

Earnings per share (EPS)-1.05
Gross Margin11.26%
Net Profit Margin-9.41%
Debt/Equity Ratio27.3%

How did PPGN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/05 01:19
End of Day Share Price 2025/10/03 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PolyPeptide Group AG is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Konstantin WiechertBaader Helvea Equity Research
Volker BosseBaader Helvea Equity Research
Thomas MeyerBaader Helvea Equity Research